24/7 Market News Snapshot 24 Jul 2024 – Sangamo Therapeutics, Inc. Common Stock (NASDAQ: SGMO)

July 24, 2024 6:18

Press Release

DENVER, Colo., 24 July, 2024 (247marketnews.com) – (Nasdaq:SGMO) are discussed in this article.
Sangamo Therapeutics, Inc. (SGMO) experiences a significant surge in the pre-market session, with shares trading at $0.506—an impressive increase from the previous closing price of $0.401, supported by a trading volume of 5.6M shares and a notable 21.11% change since market opening. This positive movement reflects heightened investor optimism, potentially influenced by recent developments or market expectations. Analysts suggest closely monitoring this uptrend for potential investment opportunities amidst Sangamo Therapeutics’ promising growth trajectory in the biotech sector.

In collaboration with Pfizer Inc., Sangamo Therapeutics unveils promising results from the Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec—an investigational gene therapy designed for adults with moderately severe to severe hemophilia A. The trial demonstrates the therapy’s superiority over routine prophylaxis, showcasing a substantial reduction in annualized bleeding rates from Week 12 onwards, indicating significant improvements in patient outcomes. Lead investigator Professor Andrew Leavitt highlights the transformative impact of giroctocogene fitelparvovec in alleviating the treatment burden for hemophilia A patients, with superior bleed protection compared to conventional therapies.

The trial further showcases the therapy’s favorable safety profile and potential for long-term bleed protection through a single infusion, providing a promising alternative for individuals with hemophilia A. Pfizer plans to engage with regulatory agencies to discuss the compelling trial results and explore opportunities for therapy advancement and potential commercialization. Giroctocogene fitelparvovec, with its Fast Track and Regenerative Medicine Advanced Therapy designations, represents a significant advancement in hemophilia A management, reflecting Sangamo Therapeutics’ commitment to pioneering genomic therapies to revolutionize patient care.

As additional data analyses continue, forthcoming medical meetings will offer deeper insights into the therapy’s promising outcomes. Sangamo Therapeutics remains dedicated to delivering innovative genomic medicine solutions, with giroctocogene fitelparvovec poised to reshape the hemophilia A treatment landscape. For further details on Sangamo Therapeutics and its transformative genomic initiatives, visit www.sangamo.com.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.